GOBEL, BRITTA,SOMMERFELD, MARK,BOSCHEINEN, OLIVER,LANGER, THOMAS,RUDOLPH, CHRISTINE,EVERS, ANDREAS
申请号：
CA3047862
公开号：
CA3047862A1
申请日:
2017.12.22
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist / FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.
